Purdue Pharma Announces Patent Agreement with Egalet and Acura

Agreement Settles Abuse-Deterrent Formulation Patent Claims

Stamford, Conn. – May 23, 2016 – Purdue Pharma L.P. today announced that the Company has entered into an agreement with Egalet Corporation and Acura Pharmaceuticals, Inc. that will settle various patent claims. As part of the agreement the companies will exchange valuable patent and regulatory rights, and will enable all three companies to develop and sell several opioid pain medicines with abuse-deterrent properties.

“This agreement reflects the commitment of Purdue Pharma to seek solutions that will enhance collaboration in the fight against prescription drug abuse,” said Philip C. Strassburger, Senior Vice President, General Counsel. “It serves an important public health purpose to move the innovation in abuse-deterrent technologies forward.”

The abuse and misuse of prescription opioids continues to be a national health issue. For more than a decade, pharmaceutical companies have invested in opioids with abuse deterrent properties (OADPs), which make it more difficult for individuals to manipulate medications intended for patients with legitimate medical needs. This area of innovation has been recognized and encouraged by the U.S. Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA) and the White House.

OADPs hold promise as their abuse-deterrent qualities continue to improve and as they become more widely available. Part of the FDA’s Opioid Action Plan is to expand access to OADPs, which are designed to resist manipulation of the medicines so they cannot be snorted or injected.

About Purdue Pharma L.P.

Purdue Pharma is a privately-held pharmaceutical company and is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. Purdue Pharma is engaged in the research, development, production and distribution of both prescription and over-the-counter medicines and hospital products. With Purdue Pharma’s expertise in drug development, commercialization, and life-cycle management, the company is diversifying in high-need areas to expand through strategic acquisitions and creative partnerships. For more information, please visit www.purduepharma.com.

# # #

Media Inquiries:

Catherine London
Head of Corporate Communications
Purdue Pharma L.P.
203-588-7530
catherine.london@pharma.com

Close

We’re setting a new standard at Purdue Pharma, by learning from the past while focusing on the future. Watch here to learn more.

 
Skip the Video
-->